CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 22,502 enrolled
Drug / intervention
mRNA-1010 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05566639
NCT05566639Phase 3Completed
CompareCT.gov

A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older

ModernaTX, Inc.·interventional·Posted Oct 4, 2022·Updated Jan 16, 2025

In Brief

A Phase 3 clinical trial evaluating mRNA-1010 and Fluarix Quadrivalent for Seasonal Influenza. Completed, enrolled 22,502 participants across 233 sites in 11 countries.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of mRNA-1010 in preventing seasonal influenza in adults 50 years and older.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Influenza
CountriesBulgaria, Canada, Denmark, Estonia, Germany, Netherlands, Poland, Spain, Taiwan, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedOct 4, 2022
Enrollment StartSep 14, 2022
Primary CompletionJan 5, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 3.7 years ago

Interventions

mRNA-1010biological

Sterile liquid for injection

Fluarix Quadrivalentbiological

Sterile suspension for injection.